ArticleActa ophthalmologica2025
Cumulative incidence of macular edema in non-infectious uveitis indicates an early therapeutic window.
Article in Acta ophthalmologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Timing of corticosteroid-sparing therapies in non-infectious uveitis: a population-based cohort study from Denmark.Eye (London, England) · 2026Article
- Cumulative incidence of macular edema in non-infectious uveitis indicates an early therapeutic window.Acta ophthalmologica · 2025Article
- Impact of socioeconomic factors on cardiovascular diseases, diabetes and all-cause mortality in patients with uveitis: a Danish cohort study.BMJ public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeUveitis-associated macular edema (UME) is a significant cause of visual impairment in non-infectious uveitis (NIU). However, the UME incidence remains unclear. Here, we evaluated the cumulative incidence of UME.
methodsMedical records of patients registered with a uveitis diagnosis code between 2010 and2024 were assessed to validate uveitis diagnoses of the patient registry of the North Denmark Region, a region of 600 000 inhabitants. Positive predictive values (PPV) were calculated for uveitis diagnosis and subtypes. The data from medical records were used to estimate prevalence, incidence and cumulative incidence of UME. The group differences were analysed by chi-squared test and cox proportional-hazards model.
resultsA total of 1476 medical records were reviewed. The PPV for a uveitis diagnosis was 92.2% (95% CI: 90.7-93.5) and 88.4% (95% Cl: 86.8-90.0) for uveitis subtypes. Among 1218 patients with NIU, 6.9% had UME at referral. During follow-up, 8.3% of the NIU patients developed UME with an incidence rate of 1.4 per 100 person-years (95% CI: 1.3-1.7) and a cumulative incidence of 10.7% (95% CI: 8.5-13.5). A higher incidence of UME was observed for patients with bilateral uveitis, systemic disease, intermediate uveitis, posterior uveitis and panuveitis (p < 0.001). A substantial increase in the cumulative incidence of UME was observed in the first 2 years post-referral.
conclusionThe high PPV supported the registry's reliability for uveitis research. UME was frequently present at the first uveitis clinic visit. NIU patients were at heightened risk of UME within the first 2 years after referral, indicating an early time window with a critical need for inflammation management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.